New study: Effect of Adalimumab in MPS I, II and VI


Title: Pilot Study of the Effect of Adalimumab on Physical Function and Musculoskeletal Disease in Mucopolysaccharidosis Types I, II and VI

Brief summary: This study is being conducted at Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). The purpose of this study is to collect preliminary data on whether the drug adalimumab (also called Humira) can decrease pain and stiffness through decreasing inflammation and antibodies against enzyme replacement therapy (ERT), and whether it is safe in people with mucopolysaccharidosis (MPS) types I, II or VI. We are looking to enroll individuals with MPS I, II, or VI who have significant pain and stiffness for this 32 week study. Study visits will be performed at LA BioMed at baseline, 16 weeks, and 32 weeks.

Please contact either Dr. Lynda Polgreen (study principal investigator) at (310) 222-1961 ( or Nathalia Cressey (study coordinator) at (310) 597-1960 ( for more information.

This entry was posted in News. Bookmark the permalink.

Comments are closed.